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INTRODUCTION
The significance of allergic and anaphylactic manifestations in many
disease conditions has become recognized with advances in medical knowledge.
However, the principle mediator of allergic and anaphylactic reactions has
not been adequately documented. Biologically active substances which have
been implicated as mediators of allergic reactions include histamine, acetyl-
choline, serotonin, bradykinin, heparin, leucotaxin, slow reacting substance
and complement.
It has long been assumed that histamine plays a role in allergic reac-
tions and that it may in part be responsible for many of the clinical signs
of allergy. Unfortunately, histamine has become established in some litera-
ture as the primary cause of allergic and anaphylactic reactions without due
regard for its pharmacologic limitations and without adequate supporting evi-
dence.
Advances in the study of histamine have been slow in spite of the volumi-
nous literature available from scientific investigation. Species variation in
response to exogenous histamine is well documented in the literature and has
been responsible for widely varying results. However, consideration of the
dosage and method of administration of histamine seems to be lacking in the
literature.
The successful treatment of allergies involving the respiratory and
integumentary systems of man with histaglobin (human gamma globulin, histamine
and sodium thiosulfate) has been reported in Europe in the past few years
(Gelfand et. al. 1963). A similar product, Hapamine 1 , containing histamine
Parke Davis and Company. Detroit, Michigan.
and protein, derived from equine serum, is available for treatment of various
allergic diseases of man in the United States. Histamine has been recommended
for therapy of allergic conditions in dogs (Schirmer, 1965); however, its
therapeutic value is questionable on clinical trial and has been nearly dis-
continued. A survey of the literature failed to reveal studies on the possi-
ble antigenicity of histamine in the human or animal subject. Consequently,
a determination of the tolerance and antigenic response appeared to be of
value and was incorporated into this study.
Alterations produced in the blood during allergic and anaphylactic reac-
tions have been demonstrated by several workers, (Webb, 1924; Dean and Webb,
1924b; Campbell et. al., 1935; Biggart, 1932; Litt, 1964). Investigations of
hematologic changes induced by exogenous histamine have centered primarily on
the eosinophil response. Changes in other fractions of the blood have not been
adequately established.
The purpose of this study was to investigate the clinical and hematologic
response induced by sublethal doses of histamine over an extended period of
time in the dog. The parameters which were investigated with regard to the
effect of exogenous histamine injection were the cellular elements of the
blood, the coagulation mechanism, clinical signs and the possible existence
of a tolerance phenomenon.
LITERATURE REVIEW
Histamine was first synthesized in 1907 as a chemical curiosity (Windaus
and Vogt, 1907). Abel and Kubota (1919) first identified histamine as the
essential depressor constituent of a number of animal organs and tissues and
suggested there was a similarity between the effects of injected histamine
and anaphylactic symptoms.
Dale (1929) stated that sufficient evidence existed for regarding hista-
mine as the physiological agent responsible for the relaxation of muscle tone
of the small blood vessels in response to irritation or injury of the tissue
and for the initial phase of the response to an injury more severe in degree.
Histamine appeared to increase the rate of healing in its early phases follow-
ing linear surgical wounds in the rat (Boyd and Smith, 1959).
The first limitations of the histamine theory were suggested by Dale
(1929) who proposed that a fully developed, local inflammatory reaction
involved much that histamine could not reproduce. He specified the wandering
of leucocytes, the leakage of erythrocytes into the injured tissue, and throm-
bosis with resulting arrest of the circulation as examples of changes not
attributable to histamine. He noted that certain features of the anaphylactic
reaction, such as the loss of coagulability of the blood, thrombosis, hemor-
rhage and necrosis could not be produced by direct injection of histamine. He
further pointed out that there was no justification to a supposition that hista-
mine was the only cell constituent liberated by injury. He did suggest, how-
ever, that only histamine might be liberated, or only its effects were visible,
in a mild injury. Nielsen and Feigen (1962) confirmed this supposition by
demonstrating that in the late stages of anaphylactic release of active materi-
als, after the degradation of histamine became dominant, there was a sudden
upsurge in the bio-assay which was due to the elaboration of a new material.
Critics of the histamine theory continued to question its validity.
Best and McHenry (1930) stated that histamine had not been established as the
causative agent of any pathological condition. Katz and Cohen (19*11) reported
that although the fact that histamine was responsible for many of the signs
observed in allergic responses seemed to be well documented in the literature,
actual experimental evidence for this hypothesis was very meager and circum-
stantial.
The hypothesis that the liver is the primary shock organ in the dog has
become well established in the literature (Dean and Webb, 1924; Dale, 1929;
Ojers, Holmes, and Dragstedt, 1941 and Melli, 1963). Even so its relation-
ship with histamine is still somewhat obscure. The liver tissue of the canine
has been found to contain 33 mg histamine per kg (33 mcg/g) by Best and
McHenry (1930) and 8-110 mcg/g by Feldberg (1956). The average weight of the
liver was 450 gm in 91 dogs with an average body weight of 13.3 kg. (Miller,
Christensen, and Evans, 1964). By calculation the liver from a dog weighing
13.3 kg contains 3.6 to 49.5 mg of histamine. It would, therefore, be possi-
ble for sufficient histamine to be released to produce histamine shock. In
the dog the specific anaphylactic reaction produced by antigen-antibody com-
plex chiefly affects the liver cells. When liver cells are injured by immune
reactions occurring in the protoplasm, histamine is released in such quanti-
ties as to produce effects not only on the vessels but on the histamine sensi-
tive cells of the body (Dale, 1929). Ojers, Holmes, and Dragstedt (1941)
obtained biopsy specimens of liver before and after an injection of equine
serum in equine-serum-sensitized dogs and found that the histamine lost by the
liver was adequate to account for the degree of shock displayed. Release of
the maximum concentration of histamine following antigen injection was found
to occur in 3-10 minutes by Code (1939) and in 60 seconds by Spink, Chartrand,
and Davis (1963). Other tissues may participate to a lesser degree. Katz and
Cohen (1941) found that when blood from a patient sensitive to an allergen was
incubated with an extract of that allergen, the plasma histamine rose consider-
ably.
The destruction of histamine was thought to be quite rapid in the body
since blood pressure returned to normal within 15-20 minutes following injec-
tion (Spink, Chartrand, and Davis, 1963). A study of the distribution of the
histamine destroying enzyme, histaminase, in canine tissues revealed that the
kidney and intestine were the richest sources; lung and blood contained moder-
ate amounts; skeletal muscle, liver, spleen and stomach contained very little
and the heart contained none (Best and McHenry, 1930).
Present views concerning the manner in which antigens release histamine
from sensitized tissues fall into two principal categories embodied either by
the enzymatic hypothesis or the displacement hypothesis (Nielsen and Feigen,
1962). The displacement theory postulates that organic bases penetrate the
mast cell and enters the intracellular granules to release histamine, thought
to be loosely linked by ionic affinity to acid groups. (Uvnas, 1958)
The enzymatic hypothesis postulates that enzymatic disruption of the ana-
tomical structure or permeability barrier of the mast cell apparently suffices
to cause a release of intracellular histamine (Uvnas, 1958). Histamine release
in guinea pig tissues as a result of antigen-antibody reactions has been
ascribed to an energy-requiring enzymatic process, since the histamine release
is reduced by oxygen lack, iodo-acetic acid and other metabolic inhibitors
(Mongar and Schild, 1955).
Eosinophilia has long been associated with allergic responses in animals.
A heterogeneous group of pathologic conditions are known to be associated with
a local or systemic eosinophilia, e.g. allergic conditions such as asthma and
hay fever, metazoal parasitic infestations, certain nonbacterial skin diseases,
Hodgkin's disease, malignant tumors and convalescence following infectious
diseases (Campbell et. al., 1935). Litt (1964) maintains that there is a degree
of eosinophilia at some stage of virtually all pathologic conditions and that
the relationship of allergy and eosinophilia should be reviewed. He suggests
that no specificity is attributed to the presence of eosinophils in tissue
where along with plasma cells, they are regarded as being indicative of the
chronic ity of a lesion, while eosinophilia is considered as indicative of an
allergic response and of a process which has the high order of specificity
typical of any immune response. As early as 1932, Biggart gave repeated
injections of protein intramuscularly as well as subcutaneous ly and produced
a general eosinophilia in guinea pigs. The eosinophil reaction became more
marked with each successive injection. Later investigation showed that local
eosinophil accumulation was not produced by the injection of foreign proteins
if an allergic reaction did not occur. Eosinophilia was produced with suc-
ceeding injections under conditions compatible with the occurrence of an aller-
gic reaction, i.e. a time interval following the first injection which would
correspond to that necessary for sensitization to develop (Campbell, Diennan,
and Rettie, 1935). More recent studies with the electron microscope have
shown the presence of immune complexes within the cytoplasm of eosinophils
thus providing evidence at a molecular level that at least one of the functions
of the eosinophil in allergic reactions is the phagocytosis of antigen-antibody
complexes (Campbell, Diennan, and Rettie, 1935; Sabesin, 1963; and Litt, 1964).
Litt (1964) demonstrated that lymph nodes exhibit substantial eosinophil
accumulation following a single stimulus in response to antibody accumulation
during the primary immune reaction.
It has long been theorized that histamine release associated with cellu-
lar injury, was responsible for the eosinophilia following foreign protein
injection or allergic responses. If true, then it would appear that hista-
mine injection should elicit eosinophilia similar to foreign body injection
or contact with natural allergens. Vaughn (1953) produced eosinophilia in
the guinea pig by injecting 0.25 mg histamine. However, when a single dose
of histamine of sufficient amount to produce obvious clinical signs (sweating,
gasping for breath, etc.) was given either intravenously or subcutaneous ly to
the horse, there was a marked diminution in the number of circulating eosino-
phils (Archer, 1963). Archer further observed that some of the eosinophils
disappeared from the circulation within five minutes with a decrease to the
lowest level in about two hours. Thereafter, the number of eosinophils
returned to pre-injection levels at about the 8th or 10th hour. In contrast
to this, if an intravenous infusion of histamine was given continously over
a two hour period, an immediate eosinopenia follows as before within five
minutes, but at approximately one hour the eosinophils return to the starting
level. Thereafter, they increase so that a peripheral blood eosinophilia is
found. Suyuki (1963) concluded that intravenous injection of histamine in
doses of 0.05-1.0 mg per kg body weight produced a marked acceleration of 17-
hydroxycorticoid secretion in the dog. Code and Mitchell (1954) found a high
concentration of histamine occurring in association with large numbers of
eosinophils in the blood of the dog. Based on these reports there would seem
to be some confusion in the literature in regard to the response of eosinophils
to injections of histamine in the various species.
A most characteristic sign of anaphylaxis in the dog is the increased
clotting time of blood (Dale, 1929, Jaques and Waters, 1941, and Rocha e
Silva, 1955). The anticoagulant substance responsible for this characteristic
prolongation of the clotting time in anaphylactic shock is heparin (Jaques
and Waters, 1941 and Rocha e Silva, 1955). Liberation of histamine during
anaphylaxis in the dog appears to be correlated with the release of heparin,
and although there was no strict parallelism, the release of both substances
probably depends upon an analogous mechanism (Rocha e Silva, 1955).
Current concepts of canine shock are inconsistent with earlier reports.
Brewer (1965) reported that in the early stages of shock, the blood has a
reduced coagulation time and intravascular clotting may occur, especially in
the stagnated microcirculation of the small intestine, thus interferring with
metabolism of the tissues and causing their breakdown with extensive ecchym-
otic hemorrhages. Also, stagnation of the splanchnic pool as a result of
hepatic vein stricture, leads to contamination of the blood stream by coli-
form organisms and their toxins. Robb (1963) demonstrated platelet emboli in
small diameter vessels in various types of experimental shock. Microscopic
observations of living blood vessels in the gut, mesentery, liver and lung
showed that micro-emboli formed after severe hemorrhage, trauma to the vessels,
anaphylaxis, norepinephrine injection and injections of coagulase positive
Staphylocci and Escherichia coli . He further concluded that the large number
of platelet emboli formed could account for the hypocoagulability of blood
and for the reported drop in platelet count following prolonged shock.
The direct effects of histamine altering the coagulation mechanism are
not adequately documented in the literature. Morgan et. al. (1959) found no
changes in clotting time of blood in dogs following intravenous histamine
injection. Dale (1929) believed that the loss of the coagulability of the
blood was not a feature of the histamine reaction. However, Bierman et. al.
(1951) reported an immediate decrease in clotting time in humans following
intravenous administration of histamine phosphate. Therefore, it appears
that the phenomenon is subject to some controversy.
With the exception of a reference by Wintrobe (1961) relating to an
increase in platelet count, detailed study of the coagulation factors follow-
ing histamine administration seems to be lacking.
Histamine produces a generalized dilation of the capillaries and contrac-
tion of small arteries and veins (Rocha e Silva, 1955). It has been thought
to be the only substance known capable of dilating capillaries and increasing
their permeability. Evidence supporting the supposition that it is the physi-
ological agent responsible for the relaxation of the tone of the small blood
vessels in response to irritation or injury of the tissues appeared to be
available as early as 1929 (Dale).
In the dog, the injection of 10 mg of histamine diphosphate per kg of
body weight elicited a fall in arterial blood pressure with a return to the
initial level after two hours. Afterwards, a slow drop in blood pressure was
observed leading to the death of the animal. During the secondary reaction,
hemoconcentration up to 130 per cent of the initial value occurred (Smith,
1928). Small doses of histamine administered intravenously to the dog and cat
do not produce alterations in the packed cell volume (Morgan et. al. 1959).
In both sensitized and normal dogs, the intravenous injection of 20 cc
of equine serum is followed by an abrupt rise of red cells per cubic milli-
meter as well as a rise in the level of hemoglobin in the peripheral blood
(Dean and Webb, 1924b). They recorded an intense leucopenia followed by a
well marked leucocytosis. Sections taken from lung tissue of dogs injected
with equine serum revealed enormous numbers of polymorphonuclear cells (JMN)
adhering to the capillaries (Webb, 1924). The first and most important change
following equine serum injection in the sensitized dog was extreme congestion
of the liver and gall bladder (Dean and Webb, 1924).
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Local eosinophil concentration may be found in the intestinal mucosa
during digestion in the guinea pig, rabbit and dog (Biggart, 1932). No local
eosinophil accumulation was observed in animals which had been starved for
two days. Selye (1938) observed an increased absorption of histamine in the
intestinal tract in stressed animals. Oral doses of histamine that were com-
pletely harmless in the normal guinea pig produced severe signs of intoxica-
tion and death in animals subjected to prolonged and exhaustive work (Rocha e
Silva, 1955). Ivy and Javois (1924) reported that 500 to 700 mg of histamine
administered orally to dogs would not produce signs of acute intoxication.
11
MATERIALS AND METHODS
Experimental Animals
Eight mongrel dogs ranging from one to three years of age were employed
in this investigation. The experimental animals were maintained in the small
animal ward in the Department of Physiology. A preliminary period consisting
of a minimum of fourteen days was allowed for conditioning the dogs to their
environment and ration. 1 During this period, the dogs were examined for para-
sitism, treated if necessary, and blood urea nitrogen2 determinations made to
verify relatively normal kidney function. (See Table 1)
The animals were randomly divided into two groups of four animals each.
Group I (animals I-IV) received subcutaneous injections and group II (animals
V-VIII) received intravenous injections. Animals I and V were retained as
controls and received only saline on comparable volume basis. The remaining
animals in group I (II-IV) received histamine base at a dosage of 0.5 mg per
kg subcutaneous ly while the remaining animals in group II (VI-VIII) received
0.2 r^g per kg histamine base intravenously.
The study was conducted over a period of three months. Twenty-five
blood sample determinations were performed on each experimental animal in
group I and 22 blood sample determinations were performed on each animal in
group II for a total of 188 blood sample determinations.
The experimental animals in group I were on continuous study for a
period of 36 days. Histamine injections were initiated on the fourth day and
continued twice daily until the 20th day at a level of 0.5 mg per kg body
weight. An additional histamine injection was administered on the 32nd
xGaines Meal: General Foods Corporation, White Plains, New York
2Bun-0-Graph : Haver-Lockhart Laboratories, Kansas City, Missouri
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day of the experiment for a total of 35 injections.
The experimental animals in group II were maintained on experiment for
28 days. Histamine injections were initiated on the fourth day and continued
twice daily until the 20th day at a dosage level of 0.2 mg per kg body weight
for a total of 34 injections.
Table 1: Initial Examination
Breed Dog Sex •We ight
Ckg)
BUN
(mg/lOOml)
Comments
Sheltie Mix I F 12.4 12-15 Toxocara canis
Beagle Mix II F 14.0 15-17 No ova demonstrated
Cocker Mix III
IV
M
M
10.9
21.6
15-17
12-14
Dipylidium caninum
German Shepherd Toxocara leonina
Terrier Mix V F 11.8 15-17 Dipvlidium caninum
and Toxocara canis
Collie Mix VI M 22.5 12-15 No ova demonstrated
Wirehair Terrier VII M 12.0 15-17 Ancylostoma caninum
Terrier Mix VIII M 10.9 12-15 No ova demonstrated
Sampling Procedure
Normal values for each animal were established by taking blood samples on
alternate days (-4, -2 and days) before histamine or saline injections were
initiated. This method was employed so that each animal would represent an
individual study, with a control and experimental phase.
Histamine injections were initiated on day and continued twice daily
until day 15. One additional injection of histamine was made on day 28 to all
animals on subcutaneous injection studies. Saline injections were given to
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control animals on the same schedule.
Serial blood sample determinations were
made 15 minutes pre-histamine
injection and 15, 45, 90, 150, and 2.0 minutes
post-histamine injection on
day and day 16. Serial blood sample
determinations made on days 4, 8, 12
and 28 consisted of only two samples
taken 15 minutes pre-histamine injection
and 45 minutes post-histamirie injection.
Single blood sample determinations were made
on days 20, 24 and 32.
These were determined on days in which no
histamine was administered.
The plan consisted of establishing normal
values for each animal on days
-4, -2 and 0. A Period of day to day 16 in
which histamine was administered
twice daily and samplings made on days 0, 4, 8,
12 and 16. All animals were
maintained from day 17 to day 24 without histamine
administration and samplings
made on days 20 and 24. The study was continued
on the animals receiving
histamine subcutaneously and an additional
histamine injection was made on
day 28. A final determination was made on day
32 and the study terminated.
Preparation of Histamine
Histamine base was suspended in physiological
saline at a concentration
of 25 mg per ml and divided into multiple dose
vials. To prevent decomposi-
tion these were stored at -10OC . Additional
solutions were compounded as
needed. Difficulties were encountered in weighing
histamine base due to its
hygroscopic properties and therefore absolute weights
were exceedingly diffi-
cult to obtain.
Dosage was determined on other available animals and
limited to the mini-
um level evoking clinical signs. The levels utilized
in this investigation
were 0.5 mg per kg subcutaneously and 0.2 mg per kg
intravenously. Physiologi-
cal saline was administered to control animals on
comparable volume basis.
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Procedure for Obtaining Blood Samples
Three ml of blood was withdrawn from the cephalic or lateral saphenous
vein into a siliconized syringe and distributed as follows: 1 ml into each of
two 13 x 100 mm test tubes for coagulation time and clot retraction determina-
tions and 1 ml into a 13 x 100 mm test tube containing 0.1 ml 3.8% sodium
oxalate solution, stoppered with parafilm and stored under refrigeration for
prothrombin time determination. One ml blood was then collected directly from
the needle and allowed to flow down the side of a siliconized test tube contain-
ing one drop of a 10% disodium ethylenediaminetetraacetate (EDTA) solution.
This sample was utilized for platelet, eosinophil, total leucocyte, differential
leucocyte, hemoglobin and packed cell volume (PCV) determinations.
Platelet Determination
The red cell pipette stem was rinsed in a solution of 3.6 per cent sodium
citrate and blood from the siliconized test tube containing EDTA drawn to 0.5
mark and diluted with 3.6 per cent sodium citrate to 101 mark. The mixture
was shaken for five minutes and placed in a clean Neubauer counting chamber.
The chamber was then placed in a covered Petri dish containing a piece of wet
filter paper and allowed to settle for approximately five minutes. The plate-
lets in the center square millimeter were counted under high dry lens (430x)
and multiplied by 2000.
Eosinophil Determination
EDTA anticoagulant treated blood was drawn to the 0.1 mark on a white
cell pipette and diluted to the 1.0 mark with a diluting solution which con-
sisted of 5 ml of 1 per cent eosin, 5.25 ml of acetone, and q.s. 100 ml with
distilled water. The diluting solution was compounded every three days, and
kept under refrigeration. The diluted blood in the pipette was thoroughly
mixed for approximately three minutes on a pipette rotor. The first few drops
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was discarded and then both chambers of a hemacytometer were filled. The
hemacytometer was then placed within a covered Petri dish containing a wet
filter paper and set aside for 5 minutes. Duplicate counts were made under
low power QOOx). Calculations were completed by multiplying the total count
in the entire ruled area times the dilution factor of 11.
Prothrombin Time Determination
The 13 x 100 mm test tube containing 1 ml of blood and 0.1 ml 3.8% sodium
oxalate was centrifuged, and the plasma decanted and stored in a test tube
under refrigeration immediately follow5.ng collection. The one-stage plasma
prothrombin time of Quick was used for the determination. More specifically,
0.1 ml of plasma was measured and added to a 12 x 75 mm Pyrex tube and placed
in a waterbath at 37°C, along with a reconstituted vial of Simplastin. 1 0.2
ml Simplastin was added quickly to the plasma with a blowout pipette and a
stopwatch started simultaneously. The tube was agitated immediately for good
mixing and then tilted from vertical to almost horizontal position until a
gel appeared which was the end point. Paired samples were determined and an
average reading recorded.
Coagulation Time Determination
Coagulation time was determined on blood withdrawn into a siliconized
syringe and distributed into two 13 x 100 mm test tubes at room temperature.
A stopwatch was started simultaneously as the blood was withdrawn. Starting
at two minutes after withdrawal, tube number one was tilted 45 degrees at
approximately 30 second intervals until it could be inverted 180 degrees with-
out the blood flowing. The same procedure was then repeated with tube two and
the time recorded.
Iwarner-Chilcott, Morris Plains, New Jersey
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Hemoglobin Determination
The Cyan-methemoglobin method was utilized to determine hemoglobin
values. 6.0 ml Hycel Cyan-methemoglobin Reagent 1 and 0.02 ml of EDTA-treated
blood were measured into a test tube with an Auto Dilutor. 2 The contents of
the test tube were mixed by inverting several times. This solution was trans-
ferred to a cuvette and read on a Coleman Junior Spectrophotometers at 540 mu
against a reagent blank. The optical density reading was converted to gms
hemoglobin per 100 ml blood by means of a calibrated standard curve.
The standard curve was determined by employing increasing dilutions of
the Hycel Cyan-methemoglobin Standard. 4 The optical density readings were
then plotted on straight graph paper to establish the standard curve.
Packed Cell Volume
The microhematocrit method of packed cell volume (PCV) determination was
performed with an International Micro-capillary Centrifuge. 5 Blu-Tip Capillary
Tubes 5 were filled from one-half to three-fourths of capacity from the sili-
conized test tube containing three ml of blood and one drop of EDTA. One end
of the capillary tube was sealed with clay and the tube then placed in the
centrifuge for a period of three minutes at approximately 12,000 revolutions
per minute. The PCV was then read on a standard chart in per cent total
volume. Duplicate determinations were made and an average of the two readings
recorded.
1Hycel, Inc., P. 0. Box 36329, Houston, Texas 77036
2Model 1034; Scientific Products, Evanston, Illinois
-^Model 6C; Coleman Instruments, Inc.. Maywood , Illinois
^Hycel, Inc., P. 0. Box 36329, Houston, Texas 77036
5Model MB, International Equipment Company, Boston, Massachusetts
Scientific Products, Evanston, Illinois
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Total Leucocyte Count
All total leucocyte counts were determined on a Coulter Counter 1 adjusted
to a threshold of 20 and an aperture current setting of 5. A standard dilu-
tion of 0.02 ml of EDTA-treated blood and 10 ml of saline2 was made on an Auto
Dilutor. 3 Duplicate dilutions were prepared from each blood sample. Addi-
tional dilutions were made to verify results when wide variations occurred.
Clot Retraction
Clot retraction studies were made on blood samples previously used in
coagulation time determinations. The two coagulated blood samples were
immediately placed in a waterbath at 37°C following coagulation. Visual obser-
vations were made at one-half, one, two, four and twenty-four hours to deter-
mine the degree of clot retraction as evidenced by the amount of serum expelled
and the firmness and rigidity of the clot.
Clinical Signs
Clinical signs were observed following histamine injection throughout the
investigation. The respiratory, digestive, urinary and integumentary systems,
the eye and associated structures and the general response were noted. Clini-
cal impressions were relied upon to determine the possibility of a tolerance
developing in relation to histamine administration.
^•Model A, Serial 1056; Coulter Electronics, Chicago, Illinois
2Sodium Chloride 0.85%; Scientific Products, Evanston, Illinois
3Model 2680; Scientific Products, Evanston, Illinois
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RESULTS AND DISCUSSION
Eosinophil Response (Table 2-7)
Eosinopenia occurred within fifteen minutes following histamine adminis-
tration in all subjects in eight trials. The per cent decrease in eosinophils
averaged 36.75 in the subcutaneous study and 29 .9^ in the intravenous study
45 minutes following histamine injections. An absolute eosinopenia occurred
within 45 minutes in 32 out of 33 trials. Absolute eosinopenia, 45 minutes
following histamine administration, ranged from 26.5 to 50.7 per cent of 15
minute pre- injection values in group I and 14.9 to 49.5 per cent in group II.
In the control animals, the eosinophil count increase in five of six trials in
the subcutaneous subject and two- of five trials in the intravenous subject 45
minutes following saline administration.
Eosinophil increases based on average control values established on days
-4, -2 and (Table 2) became apparent prior to histamine administration on
day 16 in group I and on day 8 in group II. An absolute progressive eosino-
philia occurred in the subjects receiving histamine subcutaneous ly and reached
a maximum average of 1074 or 233 per cent of the control values (Table 1) on
day 32. The absolute eosinophilia occurring in the subjects receiving hista-
mine intravenously was erratic. A peak of 774 eosinophils or 146.0 per cent
of average control values occurred on day 12, followed by a decline to 107.1
per cent of average control values on day 20. A maximum of 148.1 per cent of
average control values or 785 eosinophils per cmm blood occurred on day 24.
Eosinophil increases based on average values for all experimental animals
receiving histamine were markedly decreased by animals IV and VII. These ani-
mals had a relatively high eosinophil count initially and did not respond with
an eosinophil increase. Excluding these animals in computation, the eosinophil
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response would be 202 per cent of control values for group II on day 24 and
113 and 290 per cent of control values for group I on day 24 and 28, respec-
tively.
The control subject on the subcutaneous study showed an eosinophil vari-
ation of 57.5 to 305.2 per cent of control values (Table 2). The eosinophilia
was correlated with a mucoid enteritis and an infected laceration of the right
dorsal metacarpal region which was clinically evident on day 24. The eosino-
phil count remained within 129.8 per cent of control values through day 24.
The eosinophilia was maximal on day 28 at a level of 583 eosinophils per cmm
of blood and declined to 324 eosinophils per cmm of blood on day 32.
The control subject on intravenous study showed an initial high eosino-
phil count as recorded in Table 1. The eosinophil count showed a declining
trend throughout the investigation, except for a slight increase on day 8.
An eosinophil variation of 57.1 to 116.6 per cent of control values occurred
during the period of study.
Total Leucocyte Response (Table 8)
Total leucocyte values were highly variable throughout the investigation.
The total leucocyte count decreased in 14 of 18 trials in the group I and in
12 of 15 trials in group II within 45 minutes following histamine administra-
tion. The intravenous control subject responded with a leucocyte decrease in
four of five trials while a leucocyte decrease occurred in five of six trials
in the SC subject 45 minutes following injection of 0.9 per cent saline solu-
tion.
A slight increase in cell count occurred on day and 16 at 150 and 240
minutes post-injection. The increase was more predominant in group II. The
differential leucocyte count indicated that an increase in neutrophils occurred
simultaneously.
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High leucocyte values were obtained on both control and histamine injected
animals during the investigation. These values showed no correlation with his-
tamine activity or eosinophil response and appear to be normal for the environ-
ment and condition of the experimental animals.
Differential Leucocyte Count (Table 9)
Trends in eosinophil response are very closely correlated in both the
differential and eosinophil counts. The average differential count for both
the intravenous and subcutaneous subjects showed an absolute eosinopenia in
ten of eleven trials 45 minutes post-histamine injection. An absolute eosino-
phil increase on day 32 in group I was in close agreement with the eosinophil
count per cmm blood. The per cent eosinophils occurring in group II on day 24
differed from the results in Table 6 and was not increased over previous
responses
.
No variation in per cent neutrophils can be correlated with the direct
action of histamine. A slight neutrophil increase occurred on day and 16
at 150 and 240 minutes post- inject ion in both the subcutaneous and intravenous
animals receiving histamine. The per cent average neutrophils in group I
varied from 60 to 77 while those in group II varied from 62 to 81. The per
cent average neutrophils in the subcutaneous control subject ranged from 58 to
77 and 58 to 79 in the intravenous control subject.
Packed Cell Volume (Table 10)
Packed Cell Volume (PCV) studies indicate the absence of significant alter-
ations occurring following histamine administration. A decreasing trend in PCV
occurred in consecutive samples on the same day in both control and experimental
animals. This decrease was attributed to the removal of 5 ml of blood for each
determination.
A slight hemoconcentration occurred during the 15 minute post-injection
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trial on day and 16. Hemoconcentration occurred in 4
of 6 trials in the
subcutaneous experimental animals and in 6 of 6 trials in the
intravenous
animals. The average PCV increase was 2.56 for group I and 4.23
for group II.
The trend in hemoconcentration was less pronounced at the 45
minute post-
injection trial. The subcutaneous subjects showed an average hemoconcentra-
tion of 1.97 ml of RBC in 12 of 18 trials and the intravenous
subjects 1.03
ml RBC in 9 of 15 trials.
Hemoglobin Values (Table 11)
Hemoglobin values in initial samples were miscalculated due to a faulty
spectrophotometer. An attempt was made to superimpose the results on a
cor-
rected standard curve without success. The results were discarded
and a dif-
ferent spectrophotometer employed.
The hemoglobin values correlate very closely with PCV results. Hemo-
concentration occurred in 6 of 6 trials in the intravenous group 15 minutes
following histamine administration and in 3 of 4 trials in the subcutaneous
group. An increased hemoglobin value occurred in 11 of 14 trials in the
sub-
cutaneous subjects and in 12 of 15 trials in the intravenous subjects 45
minutes post-histamine injection. The increase ranged from 0.3 to 2.5 grams
hemoglobin per 100 ml of blood.
Control subjects showed a definite trend toward hemoglobin decrease at
15 and 45 minutes post-saline injection. The subcutaneous control subject
showed a decrease in hemoglobin in 1 of 2 trials at 15 minutes post-injection
of saline. A decrease in hemoglobin values occurred in 2 of 2 trials 15
minutes post-saline injection and 5 of 5 trials 45 minutes post-saline injec-
tion in the intravenous control subject.
Prothrombin Time (Table 12)
Prothrombin time for all subjects averaged 10.5 seconds with a range of
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7.6 to 15.6 seconds. Normal values usually given, range from 7 to 9 seconds,
the extreme range was due to the method employed. Values obtained compared to
normal values established prior to experimental injections, support a conclu-
sion that no significant changes can be attributed to histamine administration.
Thrombocyte Values (Table 13)
Thrombocyte values remained within normal limits throughout the study.
The mean thrombocyte value for all animals was 287,000 per cmm blood while the
high and low values ranged from 153,000 to 440,000 thrombocytes per cmm of
blood.
The results of this study are in agreement with the results of the clot
retraction and coagulation time studies in which no changes were demonstrated
following histamine administration. The critical level of thrombocytes neces-
sary for clot retraction is approximately 70,000 or less per cmm of blood.
Based on the results of this study it is concluded that histamine has no demon-
strable effect on the thrombocyte value in the blood.
Coagulation Time (Table 14)
The mean coagulation time for all animals in the study was 7.8 minutes
with a range of 4.5 to 14 minutes. No abnormal values or consistent varia-
tions occurred following histamine administration. An upper limit of 14
minutes is considered normal for this study. Prolongation of coagulation time
can be attributed to variable room temperatures throughout the study. Based
on these results, coagulation time is not altered by histamine administration.
Clot Retraction
Clot retraction studies were conducted on all blood samples previously
used in coagulation time determinations. Visual observation of the degree of
clot retraction and the firmness and rigidity of the clot showed normal pro-
gression in all samples.
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Clot retraction was complete at 4 hours, while clot rigidity and firmness
was normal at 24 hours. From the results of this study, there is no altera-
tions produced in clot retraction or more specifically, platelet activity in
the coagulation process.
Clinical Signs
Clinical signs were variable. Tolerance to exogenous histamine was not
apparent as signs were as severe at the termination of histamine injections
as they were initially. Clinical signs noted in group I included scleral
injection, salivation, lacrimation, defecation, vomition, micturition, thirst
and hyperpnea with abdominal breathing. Dog number II developed a cough and
dyspnea within two minutes following injection and exhibited only mild signs
as enumerated above. Individual variation in the target organs affected by
histamine was prevalent in this study.
Dogs number III and IV exhibited edema at the injection site on the 6th
and 7th day on experiment. Dogs numbered II and III developed a swelling and
focal induration at the injection site on the 16th day on experiment. This
reaction appeared to meet the requirements of an Arthus phenomenon.
A focal dermatitis appeared on dog number IV on the 32nd day of the experi-
ment. Histamine base injection resulted in a slight puritis, edema, and eryth-
ema of the lesion. Skin scrapings for cutaneous acariasis were inconclusive,
however, nineteen days following appearance of the lesion, skin scrapings were
positive for Pernodex canis .
Clinical signs observed in group II consisted of scleral injection, pros-
tration, abdominal breathing, salivation, lacrimation, vomition, defecation,
and micturition. Dog number VII exhibited severe respiratory embarrassment
with occasional mild signs as enumerated above.
The method of injection appeared to have very little influence on the
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induction period before appearance of clinical signs. The severity of response
was correlated with the method of histamine administration.
The health of the animals in general was not affected by histamine injec-
tions. All animals maintained or increased their body weight throughout the
investigation.
Dosage was based upon response in prior studies and adjusted to give
approximately the same response by different routes of injection. The dosage
administered in this study was 0.5 mg histamine base per kg body weight to
group I and 0.2 mg per kg body weight to group II. In general, the intra-
venous subjects showed a greater severity based upon clinical signs.
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GENERAL DISCUSSION
Response of Cellular Components
Variations noted in the total leucocyte count following histamine injec-
tion as shown in Table 3 were minor. The slight increase in cell count occur-
ring on day and 16 at 150 and 240 minutes post-injection suggested that a
leucocytosis may have occurred. This response was most predominant in group
I. The differential leucocyte count indicated that an increase in neutrophils
occurred simultaneously and may therefore be responsible for the leucocytosis.
This phenomenon may have been due to labored respiration and resulting physio-
logical leucocytosis.
The differential leucocyte count reflected the eosinophil response, but
with less accuracy than an actual eosinophil count per cmm of blood. An abso-
lute eosinopenia occurred within 45 minutes following subcutaneous and intra-
venous histamine injections in 32 of 33 trials. The lowest levels were reached
within two and one-half hours in eight of twelve trials. These findings are
in agreement with the eosinopenia found by Archer (1963) in the horse, but not
in agreement with the eosinophil ia produced by Vaugh (1954) in the guinea pig.
This difference may be due to species variation. The explanation for the
eosinopenia remains a mystery, however, several possibilities exist. Litt
(1964) found that the lymph nodes exhibit substantial eosinophilia following
a single foreign protein stimulus. Histologic studies would verify or refute
the possibility of eosinophil migration due to a histamine stimulus. Suzuki
(1963) concluded that intravenous injection of histamine produced a marked
acceleration of 17-hydroxycorticoid secretion which could result in an eosino-
penia. Marked increases in 17-hydroxycorticoid were noted within five minutes
following intravenous administration of histamine hydrochloride in the dog.
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The rapid occurrence of an eosinopenia suggests that an alteration in the
staining qualities of the eosin staining cellular components may have occurred
with a resulting change in appearance of the cell. Uvnas (1958) describes
profound morpho logical changes in the tissue mast cell when histamine is
released as a result either of an antigen-antibody reaction or the action of a
histamine liberator. The cells become degranulated and more or less lose their
staining characteristics. It would, therefore, appear that a similar phenome-
non may occur in the eosinophil in the presence of exogenous histamine.
Eosinophilia was well established on the sixteenth day following hista-
mine base injections twice daily. Additional increases in absolute eosino-
phils per cmm occurred in all experimental animals except dogs number IV and
VII during a period of eight days following histamine injections twice daily
for 19 days. Apparently the initial high eosinophilia in dogs IV and VII,
established on days -4, -2 and 0, indicated a physiopathological condition
existing which interfered with the eosinophilic response to histamine injec-
tions. An additional histamine injection on the 28th day following the initial
injection elicited an even higher eosinophilia in group I except dog number IV.
The increase in absolute eosinophils per cmm of blood was approximately 233 per
cent of the control levels established prior to the initial experimental injec-
tion. The response of animals II and III indicated that the eosinophilia may
be due to an immune response. The first definite eosinophilia developed 16
days following the first injection of histamine and continued to develop further
upon discontinuing injections for 12 days. An additional histamine injection
at that time appeared to stimulate a greater eosinophilic response as deter-
mined four days later. Litt (1964) and Sabesin (1963) found evidence that one
of the eosinophil in allergic reactions was the phagocytosis of antigen-antibody
complexes and assumed that eosinophilia was a phenomenon which occurred after
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formation of antigen-antibody complexes.
The eosinophil increase, even at the level of highest response, was less
than ten per cent of the total leucocyte count. Based on dosage level and
method of administration employed in this study, it would appear unlikely that
eosinophil levels up to 30% exhibited in animals showing allergic clinical
signs such as dermatitis, colitis, allergic rhinitis and parasitism could be
produced by histamine injections.
Hemoglobin and PCV studies indicate no changes occur ing following hista-
mine injection. Hemoconcentration did not appear to be a phenomenon of conse-
quence in this study. This is in agreement with Dale (1928), and Morgan et.
al. (1959), however, Smith (1923) found hemoconcentration occuring following
10 mg of histamine diphosphate per kg body weight. The dosage employed was
sufficient to produce death. Hemoconcentration occurred two hours following
histamine administration during the secondary reaction. Hemoconcentration,
as noted in anaphylactic shock, does not appear to be a physiopathological
response to histamine at the dosage administered in this investigation.
Coagulation Mechanism
Clotting time, clot retraction, platelet count and prothrombin time values
were within normal ranges following histamine injection. This finding is sup-
ported by Morgan et. al. (1959) and Dale (1929) in which normal values for
clotting time were found following histamine administration. Bierman et. al.
(1951) reported an immediate decrease in clotting time in humans following
intravenous administration of histamine phosphate at a level equivalent to
0.1-0.3 mg histamine base. While Wintrobe (1961) reported an increase in plate-
let count following histamine administration in humans. Species variation may
be responsible for the differences in the above described investigations.
Changes in the coagulation mechanism have been verified repeatedly in
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anaphylactic studies. Brewer (1965) found a reduced coagulation time and
intravascular clotting in the early stages of canine shock. While Robb (1963)
demonstrated hypocoaguiability of blood and a decreased platelet count follow-
ing prolonged shock. The increased clotting time of blood during anaphylaxis
found by earlier investigators (Dale 1929, Jaques and Waters 1941 and Rocha e
Silva 1955) is compatible with current concepts of anaphylaxis. However, the
absence of significant changes in the coagulation mechanism in this investi-
gation does not support the histamine theory of anaphylaxis. The hypothesis
advanced by Robb (1963) that large numbers of platelet emboli formed could
account for the hypocoaguiability of blood following prolonged shock and for
the reported drop in platelet count would appear to be highly acceptable in
light of present concepts.
Clinical Signs
Clinical signs appear in less than one minute following either subcu-
taneous or intravenous injection of histamine. The signs become progressively
more severe for approximately five minutes, than tend to subside during the
subsequent 15 minutes. The signs most commonly exhibited were scleral injec-
tion, salivation, lacrimation, severe abdominal pain, micturition, and thirst.
Intravenous administration of hifttamint DAto »t ft ~e>saga l«v«l of 0.2 mg per
kg, occasionally produced prostration. Two of tht lix animals »xhibi1
respiratory distress. Dog number III on subcutaneous study showed dyspnea and
coughing suggestive of laryngeal spasm or edema. Dog number VII responded to
intravenous histamine administration with a severe dyspnea and developed alveo-
lar emphysema during the investigation.
These results appear to be significant in that one-third of the experi-
mental subjects showed respiratory distress. The liver is assumed to be the
primary shock organ in anaphylaxis in the dog, while asphyxiating contraction
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of the bronchioles is the primary sign of anaphylaxis in the guinea pig. It
would appear that either the respiratory system or the liver may be the primary
shock organ in histamine shock in the canine.
The development of a clinical case of demodectic mange in dog number IV
following histamine injections may be of significance. Histamine injection
resulted in a slight puritis, edema and erythema of the lesion suggesting a
definite aggravation of the process. Therefore, further study of histamine
and demodectic mange is indicated.
Clinical signs did not appear to decrease in severity during the 16 days
in which histamine administration was performed twice daily. When the final
injection of histamine was administered on the 28th day to the dogs on sub-
cutaneous study, the clinical response was nearly identical to those noted
during the initial injection.
Clinical signs were not indicative of those occurring during anaphylactic
shock. The response elicted by histamine injection differed from anaphylactic
shock in several aspects. Abdominal pain was the outstanding sign in four of
six subjects. Histamine shock was rapid and severe in onset and resulted in a
vocal response and biting at the abdominal area. There was no change in appear-
ance of the mucous membranes, no secondary response and no deaths from hista-
mine shock. Anaphylactic shock, as severe in nature as the histamine shock,
would undoubtably result in a grave prognosis. Based on the impressions and
findings of this study, it would seem that histamine is not the primary sub-
stance responsible for death in anaphylactic shock.
Clinical response was suggestive of direct activation of the parasympa-
thetic nervous system reactor sites, thereby causing salivation, urination,
lacrimation, defecation and pain due to stimulation of smooth musculature of
the gastro- intestinal and urinary systems. Respiratory embarrassment could be
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due to activation of the parasympathetic nervous system reactor sites result-
ing in contraction of the smooth musculature of the alveolar ducts and bron-
chioles.
Tolerance and Antigenicity
Evidence of tolerance development was lacking following histamine injec-
tions. The severity of clinical signs were consistent following each injec-
tion of histamine throughout the experimental period.
Histamine is suspected of being responsible for an immunological response.
The occurrence of the Arthus Phenomenon in all experimental subjects on sub-
cutaneous histamine administration supports a conclusion that a hypersensitivity
had developed. Further circumstantial evidence of an immunological response is
the occurrence of a prominent eosinophil increase 16 days following the initial
injection of histamine. Based on the findings of Campbell, Drennan and Rettie
(193S), Sabesin (1963) and Litt (1964), eosinophilia occurs following formation
of antigen-antibody complex.
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SUMMARY
An absolute eosinopenia occurs within 15 minutes following subcutaneous
and intravenous injection of histamine base. Eosinophilia becomes well
established on the 16th day following initiation of histamine base injections
twice daily. The highest level of eosinophilia attained did not exceed ten
per cent of the total white cell count.
Hemoglobin and hematocrit values were within normal range throughout
histamine injection studies. Hemoconcentration did not appear to occur as
a result of histamine administration.
Clotting time, clot retraction, platelet count and prothrombin time
studies were not altered following histamine injection. Histamine does not
appear to be a factor in producing Changes in the coagulation mechanism.
Clinical signs appeared in less than one minute following either sub-
cutaneous or intravenous histamine injections. The signs most commonly
exhibited were scleral injection, salivation, lacrimation, severe abdominal
pain, micturition, and thirst.
Histamine may be sufficiently antigenic to produce antibody formation
twelve days following initial injections of histamine. This supposition is
based on the occurrence of eosinophilia and Arthus Reactions at sufficient
intervals for antibody formation to occur.
22
ACKNOWLEDGMENTS
The author wishes to express his sincere appreciation to Sister M. Clodovia
Lockette for her untiring assistance in conducting this study. Appreciation
also goes to Dr. J. E. Mosier, Dr. Harry Mussman and Dr. Arthur Andrews for
their guidance and assistance. Additional thanks goes to Mrs. Carolyn Pinney
for her assistance and advice on the various hematological determinations.
A final word of appreciation goes to my wife, Leone, for her assistance
in the initial preparation of this manuscript.
33
LITERATURE CITED
Windaus and Vogt, 1907: Ber. d. deutsch. chem. Gessell. 40:3691 as quoted
by
Dale, H. H. , 1929: Soir.e chemical factors in the control of the circula-
tion] Lancet 216:5520.
Abel and Kubota, 1919: Jour. Pharm. and Exp. Ther. 13:243 as quoted by Dale,
H. H. , 1929: Some chemical factors in the control of the circulation.
Lancet 216:5520.
Dean, H. R. and R. A. Webb, 1924a, The morbid anatomy and histology of
anaphylaxis. Jour. Path, and Bact. 74:51.
Dean, H. R. and R. A. Webb, 1924b, The blood changes in anaphylactic shock in
the dog. Jour. Path, and Bact. 27:65.
Ivy, A. C. and A. J. Varvis, 1924: Contributions to the physiology of gastri-
tis secretion. VI. The stimulation of gastric secretion by amines and
other substances. Amer. Jour. Physiol. 71:604.
Webb, R. A., 1924: The mechanism of anaphylactic leucopenia in dogs. Jour.
*Path. and Bact. 27:79-94.
Smith, M. I., 1928: Studies on experimental shock with special reference to
its treatment. Pharm and Exp. Ther. 32:465.
Dale, H. H. , 1929: Some chemical factors in the control of the circulation.
'Lancet 216:1233.
Best, C. H. and E. W. McHenry, 1930 : The activation of histamine. Jour.
' Physiol. 70:350.
Biggart, J. H. , 1932: Some observations on the eosinophil cell. Jour. Path.3
and Bact. 35:799.
Campbell, A. C. P., A. M. Diennan, and T. Rettie, 1935: The Relationship of
the eosinophil leucocyte to allergy and anaphylaxis. Jour. Path, and
Bact. 40:357.
Selye, H., 1938: Klin, Wehnsehr. 17:666 as quoted by Rocha e Silva, M.
,
1955: Histamine, Thomas, Springfield, 111. pp. 27.
Code, C. F., 1939: The histamine content of the blood of guinea pigs and dogs
during anaphylactic shock. Am. Jour. Physiol. 127:78.
Jaques, L. B. and Waters, E. T. , 1941: The identity and origin of the anti-
coagulant of anaphylactic shock in the dog. Jour. Physiol. 99:454.
Katz and Cohen, 1941: Experimental evidence for histamine release in allergy.
Jour. Amer. Med. Assoc. 117:1782.
34
Ojers, A. Holmes, and A. Dragstedt, 1941: The liver histamine in canine
anaphylaxis. Jour. Pharm. and Exp. Ther. 72:30.
Eierman, et. al. t 1951: The effect of intravenous histamine on the level of
the white blood count in the peripheral blood. Blood 6:926.
Vaughn, J., 1953: The function of the eosinophil leucocyte. Blood 8:1.
Code, C. F. and R. G. Mitchell, 1954: Histaminocytes of the blood—eosinophils
and basophils. Jour. Clin. Invest. 33:924.
Mongar and Schild, 1955: Nature, London 176:163 as quoted by Uvnas, B. 1958:
The Mechanism of Histamine Liberation. Jour. Pharm. and Pharmacol. 10:1.
Rocha e Silva, M. , 1955: Histamine. Thomas, Springfield, 111. pp. 8-52.
Uvnas, B., 1958: The Mechanism of Histamine Liberation. Jour. Pharm. and
Pharmacol. 10:1.
Morgan, N. C. et. al., 1959: An analysis of the histamine-like actions of
oxypanamine. Journ. Pharm. and Exp. Ther. 125:85.
Boyd, J. R. and A. N. Smith, 1959: The effect of histamine and a histamine
releasing agent on wound healing. Jour. Path, and Bact. 78:379.
Wintrobe , M. W., 1961: Clinical hematology, 5th ed., Lea and Febiger, Phila-
delphia, pp. 284.
Neilsen, C. B. and G. A. Feigen, 1962: Studies on the kinetics of histamine
release from normal sensitized tissue. Jour. Immun. 88:377.
Archer, R. K. , 1963: The functions of the eosinophils of the horse. Proc.
17th World Vet. Congress Vol. 1, pp. 179.
Gelfand, H. H. et. al., 1963: Evaluation of histamine-gamma globulin (hista-
globin) in the treatment of various allergic conditions. Annals Allergy,
21:150.
Melli, G. et. al., 1963: Shock organ and shock tissue in various animal species.
Acta Allergalagica, 18:188.
Robb, H. J., 1963: Role of Micro-embolism in Irreversible Shock. Ann. Surg.
158:685.
Sabesin, 1963: A function of the eosinophil: Phagocytosis of Antigen-Antibody
Complexes. Proc. Soc . Exp. Biol, and Med. 112:667.
Spink, W. 17., S. Chartrand, and R. Davis, 1963: Canine endotoxin shock: Pro-
tection against a lethal dose of endotoxin following an infusion of hista-
mine. Nature 200:465.
Suzuki, T. et. al., 1963: Effect of histamine on adrenal 17-hydroxycorticoid
secretion in unanesthetized dogs. Amer. Jour. Physiol. 204:847.
35
Litt, M. , 1964: Eosinophila and antigen-antibody reactions. Ann. N. Y. Acad.
Sci. 116:964.
Miller, M. E., G. C. Christensen and H. E. Evans, 1964: Anatomy of the Dog,
W. B. Saunders Co., Philadelphia, Penn.
Brewer, N. R., 1965: Current Concepts of Canine Shock. MPV 46:58.
Schirmer, R. G. , 1965: Summer Allergic Dermatoses in the Dog. Dog World 50:6.

37
Table 2: Pre- inject ion Eosinophil Values
Dog Status Eosinophils per cmm
No. Control Values
Day -4 Day -2 Day Ave.
I Control 253
II SC 430
III SC 540
IV SC 853
Ave. SC 608
V Control 1122
VI IV 468
VII IV 1045
VIII IV 264
Ave. IV 592
198 123 191
420 390 413
418 240 399
973 730 852
604 453 555
742 880 915
605 286 453
990 797 944
170 231 222
588 438 530
Dog Status
No.
Eosinophils per cmm
Day
Pre- inject ion Post-injection
15 tnin. 15 tnin. 45 min. 90 min. 150 -min. 240 min.
I Control 123 122 132 143 138 122
II SC 390 240 210 170 120 *
III SC 240 120 90 71 75 95
IV SC 730 215 390 400 137 132
\
Ave. SC 453 192 230 214 111 114
V Control 880 863 847 907 869 808
VI IV 286 208 178 228 72 94
VII IV 797 402 440 532 503 374
VIII IV 231 38 44 81 77 102
Ave. IV 438 216 221 280 217 190
*Samole lost through technical difficulties.
Dog
No.
Status
Day
Pre-inj.
15 rain.
4
Post-inj.
45 min.
Eosinophil
Day
Pre-inj.
15 min.
Ls per cmm
8
Post-inj.
45 min.
Day
Pre-inj.
15 min.
12
Post-inj.
45 min.
I Control 116 127 231 236 110 143
II SC 350 210 358 163 242 149
III SC 247 160 340 220 390 187
IV SC 720 462 726 363 880 660
Ave. SC 439 277 475 349 504 248
V Control 742 698 1067 935 764 767
VI IV 99 72 385 365 649 550
VII IV 891 704 770 731 1155 786
VIII IV 396 291 577 644 517 330
Ave. IV 462 356 577 380 774 555
„ , .
-
———
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Table 5: Post-injection Eosinophil Values, Day 16
Cog Status Eosinophils per emm
No. Day 16
Pre-injection Post-injection
15 min. 15 min. 45 min. 90 min. 150 nin. 240 min.
I Control 192 187 187 231 176 143
II SC 500 429 341 247 324 341
III SC 412 297 291 330 413 396
IV SC 1034 407 550 561 603 754
^
Ave. SC 649 378 394 379 447 411
V Control 566 544 561 539 523 495
VI IV 561 539 490 429 314 297
VII IV 1072 803 968 671 841 863
VIII IV 561 368 407 451 363 242
Ave. IV 731 570 622 517 506 534
Dog Status Eosinophils per cmm
, Day 20 Day 24 Ave. Per cent control values
(Table 2)
I Control 247 202 225 118
II SC 742 729 736 178
III sc 484 528 506 127
.IV SC 736 902 819 96
Ave. sc 654 719 687 134
V Control 523 633 578 63
VI IV 528 715 621 137
VII IV 572 990 781 83
VIII IV 605 649 627 282
Ave. IV 568 785 677 167
,
... —
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Table 7: Post-injection Eosinophil Values, Days 28 - 32
Dog Status Eosinophils per cmm
No. Day 28 Day 32 Per cent Control
Pre-inj. Post-in j. (Table 2)
15 tain. 45 tain.
170
285
295
120
233
I Control 583 665 324
II SC 660 451 1177
III SC * 814 1177
IV SC 990 743 869
Ave. SC 825 669 1074
Sample lost through technical difficulties.
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Table 8: Total Leucocyte Counts
Dog Status Control Values Day
No. Pre-inj. Post-in j.
Day -4 Day -2 15 min. 15 min. 45 min.
I Control 13,100 14,500 13,700 13,200 11,800
II SC 9,800 10,700 9,200 8,500 7,900
III SC 10,900 12,300 16,800 12,600 12,400
IV SC 12,000 17,200 17,100 16,300 14,900
Ave. SC 10,900 13,400 14,400 12,500 11,700
V Control 15,400 11,900 11,000 11,300 12,300
VI IV 22,500 24,600 13,500 12,500 12,500
VII IV 10,100 8,700 15,100 14,000 12,000
VIII IV 8,800 7,700 11,700 8,400 9,100
Ave. IV 13,800 13,700 13,400 11,600 11,200
Total leucocytes per cram blood
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Table 8 continued - Total Leucocvte Counts
Dog Day Day 4
No. Post- inject ion Pre- in j. Post-in j.
90 min. 150 min. 240 min. 15 min. 45 min.
I 11,900 12,200 11,600 19,700 14,800
IT 7,800 10,500 * 9,600 11,400
III 10,600 16,400 20,700 11,600 12,700
IV 21,500 27,900 22,600 19,900 17,700
Ave. 13,300 18,300 21,600 13,700 13,900
V 10,000 10,000 9,600 10,700 9,800
VI 13,800 14,200 14,400 11,800 11,900
VII 16,500 18,900 19,600 15,000 14,500
VIII 10,500 11,600 12,900 9,000 8,700
Ave. 13,600 14,900 15,600 11,900 11,700
*Sample lost through technical difficulties,
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Table 8 continued - Total Leucocyte Counts
Dog
No. Pre-inj,
15 tain,
Day 8
Post-inj.
45 min.
Day 12
Pre-inj. Post-inj
15 min. 45 tain.
I 16,500
II 13,400
III 18,600
IV 21,300
Ave. 17,800
V 11,300
VI 19,700
VII 14,500
VIII 14,200
Ave. 16,100
16,100
11,600
13,900
20,000
15,200
17,900
13,600
19,900
19,400
17,600
16,100
19,500
17,900
14,900
17,400
10,900
18,700
14,600
11,600
15,000
10,900
22,400
14,400
12,200
16,300
9,100
19,900
14,900
10 , 700
15,200
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Table 8 continued - Total Leucocyte Counts
Dog Day 16
No. Pre-inj. Post -inject ion
15 tnin. 15 min. 45 min. 90 min. 150 min. 240 min.
I 17,800 19,000 20,200 17,500 16,400 19,400
II 12,900 13,200 14,000 15,000 18,000 22,000
III 16,600 14,200 15,500 15,700 17,500 15,700
IV 11,900 9,800 10,200 12,000 13,500 14,000
Ave. 13,800 12,400 13,200 14,200 16,300 17,200
V 11,900 10,900 10,400 10,300 8,600 8,400
VI 15,200 16,700 11,700 15,600 16,400 16,900
VII 12,100 10,100 10,600 10,100 10,100 9,000
VIII 13,100 11,300 11,400 12,200 13,400 12,300
Ave. 13,500 12,700 11,200 12,600 13,300 12,700
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Table 8 continued - Total Leucocyte Counts
Dog Day 20 Day 24 Day 28 Day 32
No. Pre-inj. Post-inj.
15 tnin. 45 min.
I 17,000 19,500 15,600 17,500 15,900
II 13,800 16,800 15,600 13,100 13,400
III 15,500 15,300 19,700 14,000 16,000
IV 14,800 11,600 11,900 11,000 13,000
Ave. 14,700 14,600 15,700 12,700 14,100
V 14,500 9,500
VI 14,500 12,100
VII 12,600 10,200
VIII 12,000 10,500
Ave. 13,000 10,900
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Table 9; Differential Leucocyte Count
Dog Status Control Values Day
No. Day -4 Day -2 Pre-in jection 15 min.NEBLM NEBLM NEBLM
I Control 64 1 29 6
II SC 76 2 19 3
III SC 53 1 43 3
IV SC 63 5 2 19 6
Ave. SC 66 3 1 28 4
V Control 65 7 2 23 3
VI IV 73 4 16 7
VII IV 68 8 18 8
VIII IV 68 4 24 4
Ave. IV 70 5 19 6
66 2 26 6 74 21 5
75 2 20 3 61 2 29 7
49 6 1 36 8 72 3 20 5
56 7 30 8 62 8 21 9
60 5 29 6 65 4 23 7
69 10 14 7 69 5 24 2
67 7 21 5 69 3 20 8
71 8 17 4 83 3 11 3
50 3 36 11 65 3 24 8
62 6 25 7 73 3 18 6
N - Neutrophils
E - Eosinophils
3 - Basophils
L - Lymphocyte
M - Monocyte
Table 9 continued - Differential Leucocyte Count
49
15 min.NEB L M
Day
Post-injection
45 min.NEB L M 90 min.NEB L M
66 3 22 9
51 2 42 5
72 21 7
63 30 7
63 1 31 6
73 2 19 6
49 2 48 2
69 1 25 5
72 2 21 5
64 1 31 4
68 1 26 6
54 2 37 7
66 27 7
72 3 21 4
64 2 28 6
71 4 17 8
67 2 22 9
83 1 11 5
61 1 35 3
70 1 23 6
67 3 22 8
71 1 21 7
77 2 17 4
64 27 9
70 1 22 7
61 9 19 11
71 1 21 7
81 4 11 4
76 1 15 8
76 2 16 6
Table 9 continued - Differential Leucocvte Count
50
Day (cont
.
)
Post-injection
150 rain. 240 min.NEBLM NEBLM
Day 4
Pre-injection 15 min.NEB L M
72 IS 10
66 2 25 7
70 1 1 24 4
77 4 1 11 7
71 2 1 20 6
74 6 16 4
79 16 5
82 3 12 3
81 15 5
81 1 14 4
66 1 28 5
72 2 20 6
82 1 12 5
77 2 16 5
70 10 1 14 5
80 14 6
81 3 10 6
79 16 4
80 1 14 5
64 2 28 6
55 5 1 36 3
63 3 28 6
63 5 27 5
60 4 31 5
70 5 21 5
70 24 6
72 5 19 4
63 4 26 7
68 3 23 6
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Table 9 continued - Differential Leucocyte Count
Day 4 (cont.) Day 8
Post- inject ion 45 min. Pre- inject ion 15 min. Post-injection 45 min.NEBLM NEBLM NEBLM
70 2 25 3 64 1 27 8 69 2 25 4
50 3 42 5 65 3 28 4 54 2 38 6
60 1 33 6 67 4 22 7 71 1 22 6
76 2 18 4 68 6 20 6 75 1 19 5
62 2 31 5 67 4 23 6 67 1 26 6
79 5 14 2 69 7 18 6 65 7 1 23 4
62 C 29 9 70 3 25 4 72 2 23 3
77 4 17 2 71 5 21 3 79 7 13 1
61 5 30 4 71 2 24 3 67 3 26 4
67 3 25 5 71 3 23 3 73 4 31 3
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Table 9 continued - Differential Leucocyte Count
Day 12
Pre-injection 15 min. Post-injection 45 min.
N E B L M N E B L M
70 2 22 6
60 4 30 6
56 3 25 6
66 6 19 9
64 4 25 7
67 2 23 8
59 1 1 34 5
65 1 29 5
69 4 20 7
64 2 28 6
Day 16
"^e- inject ion 15 min.NEB L M
67 1 23 9
67 5 1 25 2
62 5 28 5
63 10 25 2
64 7 26 3
62 6 1 27 5
71 5 18 6
73 5 1 19 2
58 8 28 6
67 6 22 5
59 6 34 3
70 4 23 3
74 7 12 S
66 2 27 5
70 4 21 5
63 3 30 4
64 6 26 4
83 2 17
65 4 26 5
70 4 23 3
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Table 9 continued - Differential Leucocyte Count
Day 16 continued
Post- inject ion
15 min. 45 min. 90 mln.NEBLM NEBLM NEBLM
72 1 21 6 69 1 25 4 60 1 35 4
58 2 37 3 57 4 35 4 72 2 27 4
65 2 28 5 66 2 26 6 73 1 1 16 9
ft6 2 0" 50 2 56 4 1 34 5 70 5 19 6
57 2 38 3 60 3 32 5 72 3 21 6
58 7 30 5 61 5 31 4 67 5 25 3
59 6 31 4 61 2 30 7 67 3 24 6
72 6 1 19 2 75 4 19 2 72 8 16 4
69 2 24 5 75 5 16 4 75 2 14 9
66 5 25 4 70 4 22 4 71 4 18 6
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Table 9 continued - Differential Leucocvte Count
Day 16 continued Day 20
Post- inject ion
150 min. 240 min.NEBLM NEBLM NEBLM
59 35 6 58 2 34 5 67 27 6
76 2 19 3 80 2 11 7 50 7 38 5
75 1 1 18 5 66 1 29 4 64 2 28 6
73 5 18 4 64 4 1 27 4 72 3 22 3
75 3 18 4 70 2. 23 5 62 4 29 5
63 4 30 4 59 6 28 7 62 3 33 2
73 5 16 6 75 21 4 66 4 24 6
71 8 15 6 71 S 1 15 5 76 5 14 5
78 2 14 6 76 1 19 4 70 3 2 23 4
74 5 15 6 74 3 18 4 71 4 1 20 5
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Table 9 continued - Differential Leucocyte Count
Day 24 Day 28
Pre-injection Post- injection
N E B TLi M NEB L M N E B L M
77 2 18 3 62 3 27 8 65 4 25 6
67 5 1 22 3 56 3 27 4 64 2 30 4
56 4 34 6 68 5 20 9 57 5 33 5
66 2 1 24 7 59 6 32 2 64 5 1 22 8
63 4 1 27 5 6'+ 5 26 5 62 4 28 6
50 5 1 31 3
66 8 20 6
72 3 n 23 3
67 3 26 5
68 5 23 5
Day 32
72 22 6
56 6 33 5
55 7 32 6
69 8 19 4
60 7 28 5
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Table 10: Packed Cell Volume 1
Dog Status Normal Values
No. Day -4 Day -2 Day
Pre- in j. Post- in j.
15 min. 15 -.in. 45 rain. 90 rain. 150 rain. 240 min.
I Control 43 43.5 40 37.5 37.5 35.0 36.0 34.5
II SC 47.5 47.5 49.5 49.5 50.0 48.5 45.5 *
III SC 49.0 52.0 45.5 48.0 45.5 43.0 42.0 45.5
IV SC 47.5 45.0 46.0 44.5 ^7.0 44.0 37.5 37.0
Ave. SC 4S.0 48.0 47.0 47.5 47.5 45.0 41.5 41.0
V Control 41.5 41.0 41.0 39.5 40.0 39.0 36.0 37.5
VI IV 45.0 47.0 42.5 47.5 48.0 48.0 43.5 44.0
VII IV 48.0 46.5 46.5 52.5 49.0 47.0 42.5 41.5
VIII IV 43.5 42.5 43.5 46.5 45.0 43.5 42.0 41.0
Ave. IV 45.5 45.5 44.0 49.0 47.5 46.0 42.5 42.0
ML of red blood cells per 100 ml of blood.
Values lost due to technical difficulties.
Table 10 continued - Packed Cell Volume
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Day 4
Pre- in j. Post- in
j
15 min. 45 min.
Day 8
Pre- in j. Post- in
j
15 rain. 45 rain.
Day 12
Pre- in j. Post- in j,
15 min. 45 min.
40.5 38.0
43.5 43.5
41.5 39.0
42.5 45.0
42.5 42.5
39.5 35.0
44.5 47.0
46.0 48.0
33.5 40.5
43.0 45.0
38.5 37.0
41.5 41.0
42.0 43.0
42.0 41.0
42.0 41.5
37.0 35.0
42.5 46.5
49.5 50.5
45.0 44.5
45.5 47.0
37.5 36.0
39.0 42.0
42.0 44.0
41.0 46.0
40.5 44.0
39.0 38.0
44.5 43.0
49.0 49.0
43.5 42.5
45.5 45.0
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Table 10 continued - Packed Cell Volume
Dog Day 16 Day 20
No. Pre- in j. Post-inj.
15 min. 15 min. 45 min. 90 min. 150 min. 240 min.
I 35.5 37.0 36.0 36.0 40.0 37.0 39.0
II 41.5 43.0 45.5 41.5 41.0 40.0 43.0
III 43.5 50.5 J+6.5 41.5 44.0 40.0 41.0
IV 44.5 50.5 48.0 41.5 39.5 39.0 40.0
Ave. 43.0 48.0 46.5 41.5 41.5 39.5 41.5
V 41.0 41.5 43.0 39.5 34.5 36.5 42.0
VI 47.5 51.0 49.0 46.5 46.0 47.5 43.0
VII 48.0 51.5 47.5 46.0 43.0 44.0 44.0
VIII 43.0 47.5 39.5 47.0 41.0 39.5 45.5
Ave
.
46.0 50.0 45.5 46.5 1*3.5 43.5 44.0
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Table 10 continued - Packed Cell Volume
Day 24 Day 28 Day 32
Pre- inject ion Post-injection
15 min. 45 min.
40.0 39.5 40.0 41.0
41.0 41.0 46.5 40.5
48.0 44.0 44.5 44.5
42.0 41.5 51.0 *
43.5 42.0 47.5 42.5
44.0
42.0
44.5
47.5
44.5
^Values lost due to technical difficulties.
Dog Status >7ormal Values
No. Day -4 Day -2 Day
Pre- in j. Post- in j.
15 rain. 15 mln. ^5 min. 90 min. 150 min.
T Control 13.9 14.7 12.6 12.3 12.2 11.8 11.4
II SC * * * * * * *
III sc -V * * * * * *
IV SC * 15.4 16.0 15.2 16.0 15.0 13.0
Ave. sc * 15.4 16.0 15.2 16.0 15.0 13.0
V Control 14.1 15.8 13.9 13.2 15.5 •14.3 12.5
VI IV 14.4 15.4 14.1 15.8 15.8 15.6 14.5
VII IV 15.1 15.3 15.4 17.2 16.6 15.8 14.1
VIII IV 14.6 15.4 15.4 16.2 15.8 16.0 15.4
Ave. IV 15.0 15.4 15.0 16.4 16.1 15.8 14.7
1
Gd. per 100 ml of blood
*Value discarded because of faulty spectrophotometer
,
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Table 11 continued - Kemoglobin Values
Day (cont.) Day 4 Day 8 Day 12
Post-inj. cont. Pre-inj. Post-inj. Pre-inj. Post-inj. Pre-inj.
240 rain. 15 rain. 45 rain. 15 min. 45 rain. 15 rain.
11.1
13.6
13.6
13.6 12.2 12.6 12.2 12.6
* * * * 13.5
14.3 13.0 14.5 14.7 13.6
13.5 15.1 13.9 13.4 13.1
14.2 14.1 14.3 14.1 13.4
14.7 12.1 12.6 12.4 14.3
14.3 14.9 13.9 14.7 15.0
13.5 16.3 16.
S
17.0 17.2
14.4 14.7 15.3 15.4 14.3
14.1 15.3 15.3 15.7 15.5
13.0
14.6
13.5
15.0
14.4
Day 12 cont. Day 16
Post-in j. Pre-inj. Post-in j.
45 min. 15 rain. 15 min. 45 min. 90 min. 150 rain. 240 min.
12.2 12.4 12.8 12.7 12.0 13.1 12.8
14.1 13.9 15.1 15.6 14.4 14.1 13.7
14.8 14.7 17.2 15.6 13.7 14.5 12.8
15.0 14.5 16.3 15.
S
13.4 12.8 12.6
14.6 14.4 16.2 15.7 13.8 13.8 13.0
13.7 16.2 16.1 16.2 16.1 13.3 14.7
14.4 15.1 17.0 16.4 14.8 14.6 15.4
17.3 18.6 17.0 16.2 16.6 15.4 15.3
15.6 14.5 17.1 13.5 16.3 14.0 15.2
15.8 16.1 17.0 15.4 15.9 14.7 15.3
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Table 11 continued - ITeraoglobin Values
Day 20 Day 24 Day 28 Day 32
Pre- in j. Post- in j.
15 rain. 45 min.
12.6 14.5 13.3 14.0 13.1
14.1 12.3 13.7 15.0 13.8
13. 5 17.2 15.8 15.0 14.9
13.1 14.2 14.0 17.0 *
13.7 14.6 14.5 15.7 14.4
15.4 15.6
15.1 14.0
14.8 14.4
16.6 15.5
15.5 14.6
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Table 12: Prothrombin Time Determinations*
Dog Status Normal Values
No. Day -4 Day -2 Day C
Pre-inj. Post-inj.
15 rain. 15 rain. 45 rain. 90 rain. 150 min. 240 min.
I Control 10.3 12.0
II SC 9.5 11.0
III SC 12.9 11.0
IV SC 10.2 11.0
Ave. 10.9 11.0
V Control 8.0 10.1
VI IV 9.2 11.8
VII IV 10.3 10.2
VIII IV 11.5 11.2
Ave. 10.3 11.1
9.9 11.2 10.9 11.0 10.6 10.3
11.8 12.0 13.0 12.3 12.3 *
12.3 11.8 13.4 11.7 12.3 11.8
11.6 12.5 11.9 12.6 13.4 12.5
11.9 12.1 12.8 12.2 12.7 12.2
10.2 10.3 10.1 * 8.4 8.1
11.9 12.0 11.5 11.6 12.0 11.5
11.6 11.2 12.4 11.7 11.8 11.2
14.1 14.4 15.6 13.7 13.1 13.3
12.5 12.5 13.2 12.3 12.3 12.0
Plasma prothrombin time of Quick
*Values lost due to technical difficulties
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Table 12 continued - Prothrombin Time Determinations
Day 4 Day 8 Day 12 Day 16
Pre- in i. Post-in j. Pre- in j. Post- in j. Pre- in j. Post-inj. Pre- inj.
15 min. 45 min. 15 min. 45 min. 15 min. 45 min. 15 min.
10.5 9.7 10.9 10.7 10.2 9.9 11.9
13.3 11.2 10.3 11.6 11.1 11.3 10.3
10.
S
10.5 10.7 11.3 12.2 11.8 10.4
11.3 11.8 * 9.7 11.7 11.5 12.1
11.8 11.2 10.5 10.9 11.7 11.6 10.9
8.1 7.6 9.3 9.1 8.7 8.8 9.7
10.3 10.4 10.1 10.2 9.2 9.3 11.3
11.5 11.3 10.2 9.8 12.8 12.6 ...
12.0 11.5 9.5 9.4 9.9 10.1 11.3
11.3 11.1 9.9 9.8 10.6 10.7 10.6
•
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Table 12 cont:Lnued - Pro-thrombin Time Determinations
Day 16 cont.
Post- inj,
15 min. 45 min. 90 min 150 min. 240 min.
Day 20 Day 24
10.2 10.5 10.5 10.5 10.6 10.6 9.3
10.1 11.5 11.3 9.8 9.7 12.2 10.4
10.7 10.8 11.3 11.1 11.1 12.2 10.8
11.7 11.6 11.9 11.5 11.7 10.7 10.7
10.8 11.3 11.5 10.8 10.8 11.7 10.6
9.6 10.3 9.* 9.3 9.3 10.2 9.2
11.3 •k 10.0 12.1 9.6 11.6 8.4
9.2 8.7 8.7 8.6 8.8 8.5 8.3
11.5 11.5 11.7 11.* 11.3 10.4 10.5
10.7 10.1 10.1 10.7 9.9 10.2 9.1
Pre- injection
15 min.
Day 28
Post- inject ion
45 min.
Day 32
3.6 9.1 10.4
11.2 10.2 10.4
10.0 10.0 12.0
11.3 11.0 13.0
10.8 10.4 11.8
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Table 13: Throrabocvte Values-*-
Dog Status Normal Values
No. Day -4 Day -2 Day
Pre-inj. Post-inj.
15 rain. 15 min. 45 rain. 90 rain. 150 rain. 240 min.
I Control 352 212 220 232 232 230 239 253
II SC 230 200 227 240 213 197 200 *
III SC 440 306 288 262 278 202 243 301
IV 3C 298 263 210 270 279 216 346 268
Ave. SC 323 256 241 257 257 205 263 285
V Control 395 423 245 266 290 378 364 358
VI IV 231 250 231 234 212 193 194 216
VII IV 248 276 251 189 140 218 223 200
VIII IV 300 308 272 334 350 384 359 416
Ave. IV 260 278 251 252 234 265 259 277
•Platelets in thousand per ral of blood
"Values lost due to technical difficulties
Day 4 Day 8 Day 12 Day 16
Pre-inj. Post-inj. Pre-inj. Post-inj. Pre-inj. Post-inj. Pre-inj.
15 min. 45 min. 15 min. 45 min. 15 min. 45 min. 15 min.
290 302 254 224 320 210 248
268 270 400 247 380 362 258
222 274 314 344 430 370 303
34S 432 340 355 243 319 340
279 325 351 315 351 350 300
2S5 239 195 184 252 257 312
163 176 174 153 176 185 230
352 357 272 360 342 262 269
222 232 450 441 324 267 346
246 255 299 318 287 241 248
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Table 13 c ont inued - Thr<stnbocyte Values
Post-in;}.
15 min. 45 rain.
Day 16 continued
90 min. !L50 min. 240 min.
Day 20 Day 24
266 287 322 324 252 339 358
235 260 278 382 382 417 396
398 370 376 370 368 356 246
394 438 399 342 271 300 334
342 356 351 365 340 358 325
271 241 268 240 239 235 291
264 220 220 267 274 274 208
247 239 244 230 244 309 310
341 303 349 337 374 376 215
2S4 254 2 71 278 297 320 244
Pre-inject ion Day 28 Post:-injection Day 32
415 411 368
223 380 440
268 279 340
310 370 275
267 346 352
Dog Status Normal Values
No. Day -4 Day -2 Day
Pre- in j. Post- in j.
•15 min. 15 min. 45 rain. 90 rain. 150 rain. 240 rain.
I Control 5.5 4.5 8.5 9.0 6.5 7.0 7.0 8.0
II SC 7.0 5.0 5.0 5.5 5.0 5.0 5.5 *
III SC 5.0 6.0 5.0 * 6.5 6.0 5.5 8.0
IV SC 6.5 7.0 6.5 7.5 9.5 7.0 7.5 8.0
Ave. SC 5.2 5.0 5.5 6.5 7.0 6.0 6.2 8.0
V Control 7.0 7.0 7.5 7.5 6.5 7.5 6.0 6.0
VI IV 3.5 12.5 13.0 13.5 13.5 13.0 13.0 14.0
VII IV 10.5 13.5 9.0 7.5 6.5 5.5 7.0 6.0
VIII IV 9.0 9.0 S.5 * 10.5 9.5 7.0 6.0
Ave. IV 9.3 8.3 10.2 10.5 10.2 9.3 9.0 8.7
Method of Lee and White
*Values lost due to technical difficulties
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Table 14 continued - Coagulation Time
Pay 4 Day 8 Day 12 Day 16
Pre-inj". Post-inj. Pre-inj. Post-inj. Pre-inj. Post-inj. Pre-inj. Post-inj.
15 min. 45 min. 15 min. 45 rain. 15 rain. 45 min. 15 rain. 15 min.
11.0 10.5 10.0 9.0 8.5 8.5 12.0 10.5
5.0 6.5 7.5 5.5 5.0 5.5 8.0 7.0
6.5 7.0 7.5 7.5 8.5 12.0 7.5 10.0
5.5 S.5 5.5 7.5 11.5 13.5 10.5 13.0
5.7 7.2 6.8 6.8 8.3 10.3 8.7 10.0
7.0 6.5 13.0 8.0 7.0 10.0 8.5 9.5
8.5 10.0 7.0 6.0 8.0 12.0 * 9.0
12.0 13.0 S.O 7.0 12.5 11.5 10.5 9.5
6.0 5.0 8.5 9.0 8.5 9.5 10.0 9.0
8.8 9.3 7.8 6.7 9.7 11.0 12.5 9.2
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Table 14 continued - Coas;ulation Time
Day 16 continued Day 20 Day 24
Post- in j.
45 min. 90 min.
-
150 min. 240 min.
9.0 8.5 8.0 11.5 9.0 7.5
6.5 8.0 6.0 6.0 11.0 10.5
9.5 9.0 * 12.0 8.5 8.0
14.0 13.5 12.0 11.0 8.0 10.5
10.0 10.2 • 9.0 9.7 9.2 9.7
9.5 10.0 10.0 9.5 6.0 10.5
10.5 8.5 9.0 7.0 9.5 7.0
8.0 10.5 9.0 7.5 13.5 10.0
9.5 9.5 9.5 8.2 11.2 9.2
9.3 9.5 9.2 7.7 11.4 8.7
Pre-injection
15 tnin.
Day 28
Post-inject
45 min.
:ion
Day 32
11.0 12 .0 7.5
4.5 7 .0 7.0
* 5 .5 9.5
9.0 9 .0 8.0
8.2 7 .2 8.2
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Allergic and anaphylactic mechanisms in many disease syndromes have
become more commonly recognized. The principle mediator has not been fully
documented nor has the role of histamine been adequately defined in relation
to its basic pharmacological activity. Therefore, a study encompassing some
of the hemal factors and clinical signs was conducted in an effort to deter-
mine changes induced by sublethal doses of histamine base administered over
an extended period of time to the dog.
Eight mongrel dogs were selected and randomly divided into two groups of
four animals each for subcutaneous (SO and intravenous (IV) studies. One
animal in each group was retained as a control.
Observations included total leucocyte, eosinophil, and differential leu-
cocyte counts, hematocrit, hemoglobin, prothrombin time, clotting time, clot
retraction and platelet count determinations. These observations were made
over a period of 36 days for the animals on subcutaneous study and 28 days
for the animals on intravenous study. Normal values for each animal were
established from the results of sampling on alternate days for three consecu-
tive determinations before histamine or saline injections were initiated. A
total of 9 different serial hematological determinations were conducted on
the 4 SC study animals and 7 different serial hematological determinations
were conducted on the 4 IV study animals.
Clinical signs appeared in less than one minute following either sub-
cutaneous or intravenous injections of histamine. Histamine injections
resulted in signs of scleral injection, salivation, lacrimation, severe
abdominal pain, micturition, defecation, and prostration. However, other
changes associated with systemic allergic syndromes, such as increased clot-
ting time, hemoconcentration, leucopenia, thrombosis, and hemorrhage were not
observed. The absence of these signs would tend to confirm suggestions that
11
substances other than histamine are responsible for several of the signs of
allergic responses.
Histamine appears to elicit an antigenic response 12 days following
initial administration. This assumption is based on the occurrence of eosino-
philia and the Arthus Reaction. There was no indication that a tolerance
developed for the pharmacologic action of histamine.
Hemoglobin and hematocrit values remained within the normal range through-
out the study. Hemoconcentration did not appear to be a part of the histamine
reaction. Clotting time, clot retraction, platelet count and prothrombin
studies showed no alterations in the coagulation mechanism following hista-
mine administration.
In this study, the effects of histamine on observed hematologic factors
was confined to an eosinophil response. An eosinopenia occurred in all sub-
jects 15 minutes following histamine administration and reached the lowest
levels with 150 minutes in eight of twelve trials. Eosinophil increases
became well established on the 16th day following initiation of histamine
injections twice daily. Progressive increases were noted following additional
histamine injections. The highest level of eosinophils did not exceed ten
per cent of the total white cell count. Further studies are indicated to
clarify the eosinophil phenomenon.
Finally, there appears to be a noted absence of systemic effects follow-
ing histamine administration which can be compared with permanent changes
commonly associated with anaphylactic shock. However, the effects of hista-
mine on smooth muscle, lacrimation, scleral injection and eosinophil increases
combined with apparent absence of changes in other hemotologic factors are
consistent with findings in local allergic syndromes.
